Leerink Partners reiterated an Outperform rating and $13.00 price target on Calithera Biosciences (NASDAQ: CALA) following the company's 3Q earnings ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View

Calithera Biosciences (CALA) Files $150M Common Stock ShelfNovember 10, 2015 9:41 AM Calithera Biosciences Reports Third Quarter 2015 Financial Results and Recent HighlightsNovember 9, 2015 4:05 PM Unusual 11 Mid-Day Movers 11/9: (XOMA) (PCL) (STRL) Higher; (RCAP) (FSTR) (EVEP) LowerNovember 9, 2015 12:55 PM Calithera Biosciences (CALA) Updates on CB-839 at 2015 AACR-NCI-EORTCNovember 9, 2015 8:46 AM Calithera to Present New Phase 1 Solid Tumor Dose Expansion Data of CB-839 at the 2015 AACR-NCI-EORTC International ConferenceNovember 8, 2015 12:15 PM Calithera Presents Preclinical Study Findings for CB-1158 at the 2015 AACR-NCI-EORTC International ConferenceNovember 6, 2015 9:01 AM